Disc Medicine Inc. - Asset Resilience Ratio
Disc Medicine Inc. (IRON) has an Asset Resilience Ratio of 84.22% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IRON working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Disc Medicine Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Disc Medicine Inc. asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Disc Medicine Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Disc Medicine Inc. (IRON) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $619.07 Million | 84.22% |
| Total Liquid Assets | $619.07 Million | 84.22% |
Asset Resilience Insights
- Very High Liquidity: Disc Medicine Inc. maintains exceptional liquid asset reserves at 84.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Disc Medicine Inc. Industry Peers by Asset Resilience Ratio
Compare Disc Medicine Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Disc Medicine Inc. (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Disc Medicine Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 86.75% | $700.01 Million | $806.88 Million | +26.88pp |
| 2024-12-31 | 59.88% | $297.45 Million | $496.77 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $368.00 Million | -- |
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associ… Read more